Neurogene (NASDAQ:NGNE) Receives “Buy” Rating from HC Wainwright

Neurogene (NASDAQ:NGNE)‘s stock had its “buy” rating reiterated by HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $55.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 177.50% from the stock’s previous close.

NGNE has been the topic of several other reports. Robert W. Baird increased their target price on shares of Neurogene from $54.00 to $72.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 12th. Leerink Partners increased their target price on shares of Neurogene from $45.00 to $72.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 12th. Stifel Nicolaus increased their target price on shares of Neurogene from $44.00 to $60.00 and gave the stock a “buy” rating in a research note on Tuesday, November 12th. Finally, BMO Capital Markets cut their target price on shares of Neurogene from $65.00 to $60.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 12th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Neurogene presently has an average rating of “Buy” and a consensus target price of $63.33.

Neurogene Stock Down 42.6 %

NASDAQ:NGNE opened at $19.82 on Tuesday. The firm’s fifty day moving average is $46.80 and its 200-day moving average is $40.09. Neurogene has a 52 week low of $12.49 and a 52 week high of $74.49.

Institutional Trading of Neurogene

Institutional investors and hedge funds have recently made changes to their positions in the company. Driehaus Capital Management LLC raised its holdings in shares of Neurogene by 123.8% in the second quarter. Driehaus Capital Management LLC now owns 102,187 shares of the company’s stock valued at $3,719,000 after purchasing an additional 56,533 shares during the last quarter. Bank of New York Mellon Corp bought a new position in Neurogene during the second quarter valued at about $1,107,000. Vanguard Group Inc. grew its position in Neurogene by 906.5% during the first quarter. Vanguard Group Inc. now owns 507,483 shares of the company’s stock valued at $25,831,000 after buying an additional 457,062 shares during the period. Marshall Wace LLP grew its position in Neurogene by 37.2% during the second quarter. Marshall Wace LLP now owns 41,447 shares of the company’s stock valued at $1,508,000 after buying an additional 11,229 shares during the period. Finally, Integral Health Asset Management LLC bought a new position in Neurogene during the second quarter valued at about $2,547,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.